# Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

> **NCT00217529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00217529
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217529, "Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00217529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*